PAQ Therapeutics Unveils First Clinical Data for KRAS G12D Degrader PT0253 at EORTC-NCI-AACR 2026 Symposium#USA#Burlington#PAQ_Therapeutics#PT0253#KRAS_G12D
PAQ Therapeutics Unveils First Clinical Data for KRAS G12D Degrader PT0253 at EORTC-NCI-AACR 2026 Symposium
The upcoming EORTC-NCI-AACR Symposium will showcase PAQ Therapeutics’ promising data on their KRAS G12D degrader, PT0253, addressing unmet cancer needs.
third-news.com
November 3, 2026 at 12:27 PM
PAQ Therapeutics Unveils First Clinical Data for KRAS G12D Degrader PT0253 at EORTC-NCI-AACR 2026 Symposium#USA#Burlington#PAQ_Therapeutics#PT0253#KRAS_G12D
Astellas Initiates Phase 3 Study of Setidegrasib for Advanced Lung Cancer Patients#Japan#Tokyo#Astellas_Pharma#KRAS_G12D#setidegrasib
Astellas Initiates Phase 3 Study of Setidegrasib for Advanced Lung Cancer Patients
Astellas has commenced a Phase 3 clinical trial of setidegrasib targeting advanced lung cancer with KRAS G12D mutation, exploring new treatment options for patients.
third-news.com
September 23, 2026 at 11:34 PM
Astellas Initiates Phase 3 Study of Setidegrasib for Advanced Lung Cancer Patients#Japan#Tokyo#Astellas_Pharma#KRAS_G12D#setidegrasib
Ranok Therapeutics Reveals Promising Phase 1 Results for KRAS G12D Inhibitor RNK08954 in Lung Cancer Treatment#None#Waltham,_Massachusetts#KRAS_G12D#Ranok_Therapeutics#RNK08954
Ranok Therapeutics Reveals Promising Phase 1 Results for KRAS G12D Inhibitor RNK08954 in Lung Cancer Treatment
Ranok Therapeutics has released encouraging interim Phase 1 data on RNK08954, a KRAS G12D inhibitor, showing significant anti-tumor effects on lung cancer patients at ASCO 2026.
third-news.com
June 1, 2026 at 11:16 AM
Ranok Therapeutics Reveals Promising Phase 1 Results for KRAS G12D Inhibitor RNK08954 in Lung Cancer Treatment#None#Waltham,_Massachusetts#KRAS_G12D#Ranok_Therapeutics#RNK08954
Ranok Therapeutics Publishes Promising Phase 1a Results for KRAS G12D Inhibitor RNK08954#China#Hangzhou#KRAS_G12D#Ranok_Therapeutics#RNK08954
Ranok Therapeutics Publishes Promising Phase 1a Results for KRAS G12D Inhibitor RNK08954
Ranok Therapeutics has released positive preliminary results from its Phase 1a clinical trial of the KRAS G12D inhibitor RNK08954, showing promising efficacy in patients.
third-news.com
May 11, 2026 at 1:25 PM
Ranok Therapeutics Publishes Promising Phase 1a Results for KRAS G12D Inhibitor RNK08954#China#Hangzhou#KRAS_G12D#Ranok_Therapeutics#RNK08954
Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment#United_States#Florida_Cancer_Specialists#Fort_Myers#KRAS_G12D#setidegrasib
Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment
A Phase 1 clinical trial concluded that setidegrasib targets KRAS G12D mutations effectively, showing promise for lung and pancreatic cancer patients.
third-news.com
April 2, 2026 at 3:35 PM
Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment#United_States#Florida_Cancer_Specialists#Fort_Myers#KRAS_G12D#setidegrasib
D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications#Shanghai#USA#KRAS_G12D#D3_Bio#elisrasib
D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications
D3 Bio has received FDA clearance for two IND applications, paving the way for crucial cancer trials involving new therapeutics targeting KRAS mutations.
third-news.com
January 19, 2026 at 1:09 AM
D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications#Shanghai#USA#KRAS_G12D#D3_Bio#elisrasib
Bayer and Kumquat Biosciences Collaborate on Precision Oncology to Combat KRAS G12D Mutations#USA#San_Diego#Bayer#KRAS_G12D#Kumquat
Bayer and Kumquat Biosciences Collaborate on Precision Oncology to Combat KRAS G12D Mutations
Bayer and Kumquat Biosciences announce an exclusive collaboration to develop a KRAS G12D inhibitor, targeting high unmet needs in cancer treatment.
third-news.com
August 12, 2025 at 12:24 PM
Bayer and Kumquat Biosciences Collaborate on Precision Oncology to Combat KRAS G12D Mutations#USA#San_Diego#Bayer#KRAS_G12D#Kumquat